Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)


SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 168,575 shares of Iovance’s common stock to seven new non-executive employees.

Read more from the original source:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Related Posts